On the company's conference call, Jami Rubin at Morgan Stanley complained that Schering's guidance on Vytorin and Zetia sales amounts basically to saying they will go down.

FORBES: Magazine Article

Jami Rubin, the pharmaceuticals analyst at Morgan Stanley, points to Merck's healthy balance sheet.

FORBES: Magazine Article

Jami Rubin, the pharmaceuticals analyst at Morgan Stanley (nyse: MS - news - people ), points to Merck's healthy balance sheet.

FORBES: Forget Vioxx?

Jami Rubin, a pharmaceuticals analyst with Morgan Stanley, believes New Jersey Superior Court Judge Carol Higbee has tried, through her actions and rulings, to dissuade Merck from pursuing a long and drawn out legal fight.

FORBES: A Hopeful Sign For Merck